Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|82|1|59-66

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.1, 2012-02, pp. : 59-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 242-249

Karger

Access to resources Recommend Favorite

High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 98-103

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 67-74

Karger

Access to resources Recommend Favorite

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 620-626

John Wiley & Sons Inc

Access to resources Recommend Favorite